(MIA) and invasive adenocarcinoma (IAC). However, the genomic and immunological profiles of early stage LUAD and molecular mechanism underlying invasiveness acquisition remain unclear. Method: To understand molecular mechanism underlying invasiveness acquisition in early stage LUADs, we performed whole-exon sequencing and IHC for tumor samples in AIS (n¼8), MIA (n¼8) and IAC (n¼14) patients. Somatic mutations and copy number alterations (SCNAs) were identified and compared among three subtypes. Intra-tumor heterogeneity (ITH) analysis was performed for 20 patients with multi-region samples. Results: IAC has increased level of TMB, SCNAs, PD-L1 and CD8+ Tcells compared to the AIS/MIA groups, suggesting genomic and immune microenvironment co-evolution through invasiveness acquisition. The prevalence of EGFR mutations was 50% and 31% in IAC and AIS/MIA groups, respectively. Interestingly, less common oncogenes such as ERBB2, NRAS and BRAF were enriched in AIS/MIA groups. TP53 was enriched in IAC (36%, 5/14) compared to AIS/MIA (6%, 1/16), suggesting that TP53 may play an important role in tumor development instead of tumor initiation. ITH and branched evolution are prevalent in all three subtypes, with 18% to 95% of mutations identified as subclonal. No significant difference in subclonal proportion was observed among three subtypes, indicating ITH occurred at the very beginning of tumor initiation. Driver gene mutations including EGFR, NRAS and BRAF were all clonal. Tumors without driver mutations have higher proportion of subclonal mutations. Conclusion: IAC has district genomic and immunological profiles compared to the AIS/MIA groups. Our findings provide novel insights into genomic and immune microenvironment evolution through invasiveness acquisition in early stage LUADs and highlight the roles of ITH in LUAD initiation and development.
Background: Recent studies have indicated that anti-PD-1/PD-L1 antibodies combined with chemotherapy and/or bevacizumab could be a tolerable and effective option for patients with non-squamous NSCLC in the first line treatment. However, in second-line setting, overall response rate (ORR) of PD-1/PD-L1 checkpoint blockades used as single agent for advanced NSCLC patients who experience progression on or after platinum-based chemotherapy is limited. Therefore, we retrospectively assessed the safety and efficacy of anti-PD-1 combined with chemotherapy and/or bevacizumab as second-line treatment or beyond in patients with advanced NSCLC patients. Method: 92 Patients of stage IIIB or IV NSCLC treated with anti-PD-1 therapy in the Cancer Center of the PLA General Hospital from January 2015 to September 2017were screened for eligibility. First-line treatment were excluded. Regimens were anti-PD-1 antibody as monotherapy or in combination with chemotherapy and/or bevacizumab. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR), disease control rate (DCR) and safety profile. Results: A total of 55 patients were enrolled for the study, 33 patients were received anti-PD-1 antibody monotherapy, 22 patients were received anti-PD-1 antibody plus chemotherapy and/or bevacizumab. The PFS of anti-PD-1 combination therapy was longer than that of monotherapy group (median, 7.5 vs 3.3 months, HR, 0.349, 95% CI, 0.17-0.73, P <0.0001). 7 of 22 patients (31.8%) in the combination groups achieved an objective response compared with 3 of 30 patients (10.0%) in the PD-1 antibody monotherapy group (P¼0.075). 21 of 22 (95.5%) patients in the combination therapy achieved a disease control compared with 14 of 30 patients (46.7%) in the monotherapy group (P¼0.000). The incidence of grade 3/4 treatment-related adverse events were 2 of 33 patients (6.1%) in monotherapy group and 5 of 22 patients (22.7%) in combination group. No treatment-related mortality was observed. Conclusion: Preliminary data indicated that PD-1 based combination therapy as second line treatment and beyond exhibited a promising safety profile. More importantly, PD-1 antibody plus chemotherapy and/or bevacizumab could have a longer PFS and a higher ORR and DCR. Given the relative small sample size and limitations of retrospective observational study, the strategy needs further exploration. Keywords: non small cell lung cancer, immune checkpoint inhibitor, combination therapy
